PMID- 37178310
OWN - NLM
STAT- MEDLINE
DCOM- 20230807
LR  - 20231010
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 81
IP  - 3
DP  - 2023 Sep
TI  - Clinical characteristics and human leukocyte antigens in patients with immune 
      checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single 
      center prospective study.
PG  - 477-483
LID - 10.1007/s12020-023-03394-8 [doi]
AB  - PURPOSE: Immune checkpoint inhibitor (ICI) induced type 1 diabetes (T1D) and 
      pituitary dysfunction are life-threatening adverse events, yet there is little 
      clinical data available. We aimed to investigate the clinical characteristics of 
      patients with these adverse events and report their human leukocyte antigen (HLA) 
      profile to determine its relevance. METHODS: This is a single-center prospective 
      study. We enrolled patients with cancers who were administered ICI and diagnosed 
      as ICI induced T1D (ICI-T1D) and pituitary dysfunction (ICI-PD). Clinical data 
      and extracted DNA from blood samples were collected. HLA typing was performed 
      using next-generation sequencing. We compared our results with those previously 
      reported in healthy controls and investigated the correlation between HLA and the 
      occurrence of ICI-T1D and ICI-PD. RESULTS: We identified 914 patients treated 
      with ICI in our facility from 1st September, 2017 to 30th June, 2022. Six of 
      these patients developed T1D and 15 developed pituitary dysfunction. The duration 
      from the initiation of ICI treatment to the onset of T1D or pituitary dysfunction 
      averaged 492 +/- 196 days and 191 +/- 169 days. Among the six patients with T1D, two 
      were positive for anti-GAD antibody. The frequencies of HLA-DR11, -Cw10, -B61, 
      -DRB1*11:01, and -C*03:04 were significantly higher in patients with ICI-T1D than 
      in controls. The frequencies of HLA-DR15 and -DRB*15:02 were significantly higher 
      in patients with ICI-PD than in controls. CONCLUSION: This study revealed the 
      clinical characteristics of ICI-T1D and ICI-PD and the association between 
      specific HLAs and these adverse events.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Hara, Natsuko
AU  - Hara N
AD  - Department of Diabetes, Metabolism, and Endocrinology, Tokyo Medical University, 
      Tokyo, 160-0023, Japan.
FAU - Suwanai, Hirotsugu
AU  - Suwanai H
AUID- ORCID: 0000-0001-9102-630X
AD  - Department of Diabetes, Metabolism, and Endocrinology, Tokyo Medical University, 
      Tokyo, 160-0023, Japan. suwanai-h@umin.ac.jp.
FAU - Yakou, Fumiyoshi
AU  - Yakou F
AD  - Department of Diabetes, Endocrinology and Metabolism, Tokyo Medical University 
      Hachioji Medical Center, Tokyo, 193-0998, Japan.
FAU - Ishii, Keitaro
AU  - Ishii K
AD  - Department of Diabetes, Metabolism, and Endocrinology, Tokyo Medical University, 
      Tokyo, 160-0023, Japan.
FAU - Iwasaki, Hajime
AU  - Iwasaki H
AD  - Department of Diabetes, Metabolism, and Endocrinology, Tokyo Medical University, 
      Tokyo, 160-0023, Japan.
FAU - Abe, Hironori
AU  - Abe H
AD  - Department of Diabetes, Metabolism, and Endocrinology, Tokyo Medical University, 
      Tokyo, 160-0023, Japan.
FAU - Shikuma, Jumpei
AU  - Shikuma J
AD  - Department of Diabetes, Metabolism, and Endocrinology, Tokyo Medical University, 
      Tokyo, 160-0023, Japan.
FAU - Sakai, Hiroyuki
AU  - Sakai H
AD  - Department of Diabetes, Metabolism, and Endocrinology, Tokyo Medical University, 
      Tokyo, 160-0023, Japan.
FAU - Miwa, Takashi
AU  - Miwa T
AD  - Department of Diabetes, Metabolism, and Endocrinology, Tokyo Medical University, 
      Tokyo, 160-0023, Japan.
FAU - Suzuki, Ryo
AU  - Suzuki R
AD  - Department of Diabetes, Metabolism, and Endocrinology, Tokyo Medical University, 
      Tokyo, 160-0023, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230513
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 1/genetics
MH  - Immune Checkpoint Inhibitors
MH  - Prospective Studies
MH  - HLA Antigens
MH  - *Neoplasms
OTO - NOTNLM
OT  - Human leukocyte antigen
OT  - Immune checkpoint inhibitors
OT  - Pituitary dysfunction
OT  - Type 1 diabetes
EDAT- 2023/05/14 01:07
MHDA- 2023/08/07 06:42
CRDT- 2023/05/13 15:03
PHST- 2023/03/16 00:00 [received]
PHST- 2023/05/01 00:00 [accepted]
PHST- 2023/08/07 06:42 [medline]
PHST- 2023/05/14 01:07 [pubmed]
PHST- 2023/05/13 15:03 [entrez]
AID - 10.1007/s12020-023-03394-8 [pii]
AID - 10.1007/s12020-023-03394-8 [doi]
PST - ppublish
SO  - Endocrine. 2023 Sep;81(3):477-483. doi: 10.1007/s12020-023-03394-8. Epub 2023 May 
      13.